『80: Digital Twins and the AI Revolution in Healthcare with Andree Bates, Part 2』のカバーアート

80: Digital Twins and the AI Revolution in Healthcare with Andree Bates, Part 2

80: Digital Twins and the AI Revolution in Healthcare with Andree Bates, Part 2

無料で聴く

ポッドキャストの詳細を見る
SummaryHow do digital twins in medicine get from the lab to the patient? It all comes down to regulation, data, and trust. In this second part with Dr. Andrée Bates (CEO, Eularis), we cover the FDA Modernization Act 2022, EU AI Act conflicts with GDPR, the UK and China regulatory landscape, digital twin ownership and liability, patient-owned health data, decentralized data markets, and what it will take — technically and culturally — to make AI-powered personalized medicine real. Plus: why medical school curricula must change, and a vision of the human-AI health future. Don't miss Part 1 (EP 79) for the science and economics foundation.Key TakeawaysThe FDA's 2022 Modernization Act was a watershed moment — it replaced mandatory animal testing with "non-clinical" methods including in silico and cell-based models. 90% of drugs that clear animal studies never make it through human trials The EU faces a three-way regulatory conflict — the AI Act, the Medical Device Regulation (MDR), and GDPR have overlapping, partially conflicting requirements; GDPR's "purpose limitation" principle is structurally hostile to digital twins, which are by definition continuously updatedUS vs. EU regulatory philosophy in one sentence: the US is outcome-based and post-market weighted ("prove it works, monitor it"); the EU is process-based and pre-market weighted ("prove your development was rigorous first") — with real consequences for patient access timelinesChina is the one to watch — the NMPA accepts in silico evidence, data sharing is state-encouraged, and population-scale twins built on integrated health records are politically feasible in a way they are not in the WestOwnership of digital twins is unresolved Patients owning their own health data — including blockchain-based consent models where patients sell data case-by-case to pharma — is already being piloted in the US The full ecosystem for digital twins requires: multi-organ integration, quantum computing power, privacy-preserving AI (e.g. federated learning), faster regulatory qualification pathways, international harmonization, and a liability frameworkThe cultural gap is the hardest barrier — public trust in computer-tested drugs lags far behind trust in animal- or human-tested ones; the first major in silico drug recall, when it happens, will be a defining political momentMedical education must change — tomorrow's clinicians need to read computational evidence confidently; few medical schools teach this yetGuest Bio — Dr. Andrée BatesDr. Andrée Bates is the Chairwoman, Founder, and CEO of Eularis, AI consultancy for the pharmaceutical and life sciences industry. She hosts her own podcast with over 220 episodes on AI in pharma. 00:00 Introduction to PART 2 with Andree Bates 01:35 Regulatory Landscape for AI and Digital Twins05:22 Comparative Analysis of US and EU Regulations10:48 Global Perspectives on AI in Healthcare14:08 Future of Personal Data Ownership in Medicine17:43 Innovative Business Models for Digital Twins21:17 The Role of AI and Quantum Computing in Healthcare27:31 Building the Future of Medicine: Preconditions and InfrastructureHyperlinks:LinkedIn Dr. Andree BatersCorporate Website EularisAI in Pharma — search on Spotify/Apple Podcasts (220+ episodes)Anastassia Lauterbach - LinkedInFirst Public Reading, Romy, Roby and the Secrets of Sleep (1/3) First Public Reading, Romy, Roby and the Secrets of Sleep (2/3) First Public Reading, Romy, Roby and the Secrets of Sleep (3/3) AI Snacks with Romy and Roby@romyandroby “Leading Through Disruption”AI EdutainmentThe AI Imperative BookRomy & Roby Book
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません